TORONTO, Aug. 05, 2020 (GLOBE NEWSWIRE) — CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), has been selected by Dharma Pharmaceuticals (“Dharma”), as a preferred partner and platform to establish and generate real-world evidence (RWE) on a full suite of Dharma products in Virginia. The announcement comes ahead of Dharma’s commencement of sales of high-quality medical cannabis oils to patients in the near future. Dharma’s mission is to bring targeted medical cannabis products to Virginia’s patients.
To read the full press release from CB2 Insights, click here.
This headline brief is meant to help you stay on the pulse of your favorite cannabis-related companies. Sometimes, just figuring out which marijuana stocks may be moving can be one of the toughest parts of trading and investing in them.
Every day, The Daily Marijuana Observer seeks to keep stakeholders informed with as much of the latest news possible to keep you informed of any catalysts that may impact the companies you care about. Be sure to subscribe to cannabis stock updates here, and CB2 Insights Inc. Updates here so you never miss a thing.
Get Real-Time Updates from MJobserver.com
